Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lazar Nikitovic has a total of 3 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Development of Linear Accelerating Structures for Ion Injection into a Cancer Therapy Synchrotron and Parallel Production of Radioisotopes

    by Lazar Nikitović

    This Thesis presents the design and optimisation of a Quasi-Alvarez Drift Tube Linac (QA-DTL) for accelerating helium and carbon ions for medical applications. The proposed linac combines high acceleration efficiency, improved beam dynamics, and versatility, enabling use as a synchrotron injector and for radioisotope production. Its dual-purpose operation offers a cost-effective solution for future particle therapy facilities, supporting both advanced cancer treatment and the production of radioisotopes for medical diagnostics and therapy.

  • Lineāri paātrinošo struktūru izstrāde jonu injicēšanai vēža terapijas sinhrotronā un paralēlai radioizotopu ražošanai

    by Lazar Nikitović

    Šajā darbā aplūkota kvazi-Alvareca dreifa cauruļu lineārā paātrinātāja (QA-DTL) projektēšana un optimizācija hēlija un oglekļa jonu paātrināšanai medicīniskiem lietojumiem. Piedāvātais lineārais paātrinātājs apvieno augstu paātrināšanas efektivitāti, uzlabotu staru dinamiku un daudzpusību, ļaujot to izmantot gan kā sinhrotrona injektoru, gan radioizotopu ražošanai. Tā divējāda darbība piedāvā rentablu risinājumu nākotnes daļiņu terapijas centriem, atbalstot gan modernu vēža ārstēšanu, gan radioizotopu ražošanu medicīniskajai diagnostikai un terapijai.

  • Open Access

    A Helium Ion Linear Accelerator Optimised for Astatine Production

    by Maurizio Vretenar, Alessandra Lombardi, Lazar Nikitovic

    This paper presents the design of a linear accelerator optimised for the production of astatine-211, one of the most effective theragnostics isotopes for targeted alpha therapy of cancer (TAT). When attached to a carrier molecule that selectively binds to cancer cells, this powerful alpha emitter enables highly localised cell damage. The 11 m long linac is designed to accelerate an average current of up to 2 mA of fully stripped helium ions to 28.4 MeV, the energy required for 211At production on a bismuth target. The accelerator comprises an alpha particle source, a compact Radio Frequency Quadrupole (RFQ), and a Quasi-Alvarez Drift Tube Linac (QA-DTL). Compared with conventional cyclotron-based solutions, the proposed design provides higher beam current for increased isotope yield, together with reduced beam losses and activation. In addition, compared with a standard Drift Tube Linac (DTL) configuration, the adoption of a QA-DTL structure enables more compact dimensions and improved power efficiency.

  • Open Access

    An Alvarez-Type Linac Configuration for Future Carbon and Helium Ion Therapy Facilities with Parallel Radioisotope Production

    by Lazar Nikitovic, Maurizio Vretenar, Toms Torims

    The increasing demand for ion beams heavier than protons—particularly carbon and helium ions—for cancer therapy has driven the development of advanced accelerator technologies. Although proton therapy is well established, its physical properties limit its effectiveness against certain tumor types, thereby motivating the use of ions with higher linear energy transfer (LET) and greater biological effectiveness. This study presents the design of an Alvarez-type linear accelerator configuration that combines a Quasi-Alvarez Drift Tube Linac (QA-DTL) and a conventional Alvarez Drift Tube Linac (DTL). The proposed systems are intended for accelerating and injecting carbon or helium ions into a cancer therapy synchrotron, as well as accelerating helium ions for radioisotope production. The optimized QA-DTL and DTL structures provide a versatile and efficient solution for future particle therapy facilities, addressing the growing demand for compact, high-performance, and multifunctional accelerator systems. The proposed linac configurations are designed to operate at 352.2 MHz and consist of three sections. For accelerating low-velocity ions, the first section is a QA-DTL, which is the only section powered during the injection of carbon or helium ions (depending on configuration) into the therapy synchrotron at the energy of 5 MeV/u. The QA-DTL is followed by two DTL cavities forming the second and third sections, which further accelerate helium ions to energies of up to 7.1 MeV/u and 10 MeV/u, respectively. The energy of 7.1 MeV/u is chosen because it represents the production threshold of 211At, one of the most promising alpha emitters for targeted alpha therapy.